Past exam of the biochemistry and Molecular Biology course of the University of Cambridge / 2025 / Paper 1 / Section E

Colonumab would have to be defined by its molecular target, functional mechanism and sequence before its proposed name conveys any useful scientific information. Colon cancer is not a single unique antigen. I would begin by selecting a target expressed accessibly on the relevant tumour cells and asking whether binding should block a growth signal, recruit immune effectors or deliver a payload. A surface receptor tyrosine kinase such as the epidermal growth factor receptor is a possible mechanistic starting point, but it is also expressed in normal tissue. Differential abundance, tissue accessibility, heterogeneity and the consequences of blocking the target must therefore be tested, rather than assuming tumour selectivity.

Target validation should compare tumour specimens, relevant normal tissues, cancer cell lines and appropriate primary-cell or organoid models. Binding to a recombinant extracellular domain is useful, but a candidate should also recognize the native membrane target. Target knockout and restoration provide strong specificity controls, and testing an independently binding antibody helps distinguish loss of the target from a damaged assay. For a signalling-blocking candidate, downstream pathway responses and growth must be measured; receptor expression alone does not establish dependence on that pathway. A tumour with constitutive downstream signalling may resist receptor blockade even if the antibody binds well.

One generation route is hybridoma technology. An immunized animal supplies B lymphocytes recognizing the chosen antigen. Fusion with an immortal myeloma line can produce hybrids that combine continued proliferation with antibody secretion. The classic experiments established continuous cultures secreting antibodies of predefined specificity.^[ref] In the conventional HAT selection scheme, aminopterin blocks de novo nucleotide synthesis; an appropriate salvage-pathway-deficient myeloma parent cannot survive alone, while unfused primary B cells have limited lifespan. Suitable hybrids inherit functional salvage metabolism and immortality. HAT survival does not select the desired antigen specificity: supernatants must subsequently be screened.

I would screen many clones for binding to native target-positive cells, absence of binding to matched target-negative cells, suitable epitope and the desired functional effect. Single-cell cloning and sequence analysis establish a defined monoclonal product. Heavy- and light-chain variable sequences can then be recovered and expressed recombinantly. A mouse-derived antibody might be made chimeric by joining its variable regions to human constant regions, or humanized by grafting selected complementarity-determining regions onto suitable human frameworks. CDR grafting demonstrated that binding specificity could be transferred, but surrounding residues can influence the binding-site geometry; affinity must be rechecked after engineering.^[ref] Humanization reduces some sources of immunogenicity without proving that the final molecule cannot elicit an immune response.

A second route is antibody phage display. A library encodes antibody fragments fused to a phage coat protein, while each particle carries the corresponding genetic information. Repeated antigen binding, washing, recovery and amplification enrich binders. The original display experiments established the physical linkage between antibody-variable-domain binding and the sequence that encodes it.^[ref] For Colonumab, positive selection on native tumour target should be combined with counterselection against relevant normal cells, tag components and unrelated proteins. Immobilized-antigen binders can recognize exposed plastic-associated conformations or show display-dependent avidity, so selected fragments must be tested as soluble molecules and after reformatting into full IgG. Human donor B-cell cloning or immunization of animals carrying human immunoglobulin loci provide additional routes to human-sequence candidates.

Lead optimization combines affinity maturation, epitope mapping and functional screening. For a simple one-to-one interaction, $K_D=k_{\mathrm{off}}/k_{\mathrm{on}}$, but bivalent binding on a dense cell surface introduces avidity. surface plasmon resonance or another binding method should therefore use controls for ligand density, transport limitation and nonspecific binding. Higher affinity is not automatically better: tissue penetration, target internalization, aggregation and off-target binding also matter. Choice of antibody constant region determines properties such as effector-cell engagement and persistence; it must match the intended action.

A selected sequence can be expressed in a stable mammalian production line, commonly Chinese hamster ovary cells, and purified by protein A affinity chromatography followed by additional purification and formulation steps. The final product needs identity, purity, aggregation, glycosylation, stability and potency assays. Functional tests should compare isotype control, target-negative cells and, where relevant, an effector-silent or binding-fragment derivative to separate direct blockade from immune-mediated killing. Animal studies require a species or model in which the target and effector biology are relevant; an immunodeficient xenograft alone cannot establish normal human immune-effector activity. A binding clone becomes a therapeutic candidate only after specificity, mechanism, production quality and a plausible therapeutic window have been demonstrated; the paper supplies no data establishing that Colonumab already meets those criteria.

Dinoflagellate nuclear DNA is generally organized with far fewer canonical nucleosomes and a very different bulk packing architecture from that of familiar animal, plant and fungal nuclei. This is not equivalent to saying that dinoflagellates have no histones. The comparison must concern nuclear chromosomes, not bacterial nucleoids or organellar DNA, and must allow variation across dinoflagellate lineages.

In conventional chromatin, about $147$ base pairs of DNA wrap around an octamer containing two copies each of the core histones H2A, H2B, H3 and H4, forming a nucleosome. Linker DNA joins neighbouring particles, and histone H1 can influence linker organization. Nucleosomes compact DNA, regulate accessibility and provide substrates for histone modification and chromatin-remodelling machinery. Their spacing and higher-order contacts vary; a universal regular 30-nanometre fibre should not be assumed for all living nuclei. Wrapping is left-handed at the superhelical level, while the local duplex remains mainly right-handed B-DNA; this is not conversion of the duplex into Z-DNA.

Many dinoflagellates instead maintain conspicuously condensed chromosomes through interphase as well as division. Dense DNA arrays show liquid-crystalline chromosome organization, with ordered packing unlike a conventional beads-on-a-string nucleosomal array. Many species also have unusually large genomes and a low bulk basic-protein-to-DNA ratio. These are broad comparative trends, not proof that every dinoflagellate has the same genome size, protein complement or microscopic packing. Divalent ions, supercoiling and nonhistone DNA-binding proteins can contribute to organization, but the complete in vivo packing mechanism is not resolved by the appearance of condensed chromosomes alone.

A major discovery was the family of dinoflagellate viral nucleoproteins (DVNP). Comparative work linked the emergence of abundant DVNPs with reduced histone abundance and loss of ordinary nucleosomal organization in early-diverging dinoflagellates. These basic nuclear proteins have homologues in large DNA viruses and can associate with chromosomes.^[ref] Sequence similarity supports an evolutionary relationship; it does not by itself establish the direction of gene transfer, the exact ancestral event or the packaging role of each modern family member. Some later lineages additionally use dinoflagellate histone-like proteins, distinct from the conserved eukaryotic core histones and related in sequence to bacterial HU-type DNA-binding proteins. Calling both groups “histone-like” must not erase that distinction.

Modern sequence and protein evidence reveals retained core-histone genes and low-abundance histones in dinoflagellates. Their presence argues against an absolute histone-free description, but does not imply that they package most of the genome conventionally. They may have specialized roles; their genome-wide occupancy and precise functions need direct testing. Conversely, absence of a strong histone band in a bulk extract is not proof of complete absence, because recovery, antibody cross-reactivity and detection limits can differ among species.

The evidence comes from complementary experiments. Microscopy and chromosome birefringence test large-scale order, while nuclease digestion can test whether protected DNA fragments form a regular nucleosome-sized ladder. Standard eukaryotic chromatin is a positive control; naked DNA, undigested material and enzyme-dose series control digestion behaviour. A missing ladder is consistent with altered organization but can also result from overdigestion or unusual accessibility. Proteomics, histone-directed immunodetection and localization of candidate DNA-binding proteins address composition, while quantitative normalization to DNA is required for meaningful abundance comparisons.

A mechanistic perturbation was expression of a dinoflagellate DVNP in Saccharomyces cerevisiae. It impaired growth, associated with sites normally occupied by histones, displaced nucleosomes and impaired transcription; reducing histone abundance alleviated the toxicity.^[ref] This supports antagonism between DVNP and canonical chromatin in the tested system. Expression controls and histone manipulations help distinguish specific chromatin competition from generic protein-expression stress. However, an ectopic yeast experiment does not reconstruct the actual history of dinoflagellate evolution or establish the whole structure of a native dinoflagellate chromosome. The secure distinction is replacement of canonical nucleosomes as the dominant bulk packaging system, with retained but reduced histones and lineage-dependent alternative nucleoproteins.

Transient chemotaxis complexes have been investigated by combining biochemical reconstitution, live-cell proximity measurements, interface mapping and structural imaging. No single interaction assay establishes all of binding, signalling function and physiological timing. In the Escherichia coli pathway, methyl-accepting chemotaxis proteins form receptor assemblies with CheW and the histidine kinase CheA. Receptor stimulation regulates CheA autophosphorylation; phosphate transfer to CheY couples the input to the flagellar switch, while CheZ accelerates CheY dephosphorylation. Some receptor-scaffold contacts are relatively persistent, whereas downstream enzyme–substrate encounters are short-lived, so the premise should not imply one common lifetime for every contact.

Biochemical reconstitution first connects components to a function. Receptor-containing membranes and purified signalling proteins can be combined, supplied with labelled ATP and analysed by rapid sampling and electrophoretic separation to follow phosphorylation. Omitting and restoring CheW or another component tests its requirement, while adding the receptor's attractant tests coupling across the membrane. Reconstitution of receptor-dependent control of CheY phosphorylation established a biochemical pathway linking the receptor, CheA and response regulator.^[ref] Catalytically inactive CheA, no-ATP, no-receptor and no-ligand comparisons distinguish substrate phosphorylation from nonspecific label retention. Dependence on two proteins is functional evidence, however, not proof that they touch directly: a third protein can bridge them.

Affinity capture, co-immunoprecipitation and co-fractionation can identify associated partners, but washing can lose weak contacts and overexpression can force nonphysiological ones. A purified pair helps distinguish direct binding from bridging. Rapid or site-directed crosslinking can trap close contacts before they dissociate; complementary substitutions and compensatory mutations can then test a candidate interface. No-crosslinker, single-reactive-residue and noninteracting-partner controls are important, as are checks that the mutant proteins remain folded, localized and functional. Crosslink recovery establishes proximity within the reagent's constraints rather than a complete native binding geometry.

Förster resonance energy transfer provides a particularly informative live-cell readout. In the established chemotaxis FRET assay, CheZ fused to a cyan donor and CheY fused to a yellow acceptor report their close association. Phosphorylated CheY preferentially associates with its phosphatase, so an attractant-induced reduction in CheA activity produces a rapid decrease in the association-dependent FRET signal. Stimulus addition, removal and adaptation can therefore be followed in living cells. The original measurements used this downstream readout to probe receptor sensitivity, including receptor-modification backgrounds.^[ref]

The FRET signal is not a direct measurement of receptor–CheA binding. It depends on phosphotransfer, CheY–CheZ association, label geometry and fluorescent-protein behaviour. Donor-only and acceptor-only cells control spectral bleed-through and direct excitation; expression titration, background subtraction and photobleaching controls limit optical artefacts. Testing whether tagged proteins restore a relevant mutant phenotype checks perturbation by the labels. A binding-interface mutant should be compared with a phosphorylation-defective mutant, because either could abolish the same signal through different mechanisms. Distance-dependent transfer can be summarized as $E=1/[1+(r/R_0{)}^6]$, but converting an ensemble signal into a unique molecular distance requires assumptions about orientation and conformational heterogeneity.

nuclear magnetic resonance can map contacts at residue level. Binding-induced chemical-shift changes in labelled fragments identify affected surfaces and permit titration analysis. Work with Thermotoga maritima components mapped a receptor-contact surface on the CheA P5 domain and tested corresponding mutations in Escherichia coli using kinase activation and chemotaxis assays.^[ref] Chemical-shift perturbations can include allosteric changes as well as direct contact, and a soluble fragment can omit membrane or array constraints. Agreement among binding measurements, conservative interface mutations and preserved basal catalytic activity provides a stronger interpretation than loss of chemotaxis alone. A soft-agar migration defect can also reflect altered growth or motility rather than a particular binding defect.

Structural methods establish how such contacts fit into larger assemblies. Crystallography of domains can resolve plausible contact surfaces, while electron cryotomography images receptor arrays in near-native cells. Comparative tomography revealed a conserved approximately $12\mathrm{nm}$ hexagonal array consistent with receptor trimers of dimers.^[ref] This supports cooperative array architecture but does not directly measure the lifetime of an individual CheY encounter. Localization microscopy adds cellular position and dynamics, with resolution and labelling limits that must be stated.

The most persuasive strategy is therefore to identify a candidate contact physically, disrupt it without destroying the component, show the predicted effect in a reconstituted pathway and test the corresponding response in living cells. Adaptation studies further show why kinetic measurements matter: an interaction-dependent readout can recover after sustained input even though the stimulus remains present.^[ref] Combining controlled perturbation with independent binding, activity and cellular readouts distinguishes a real signalling interface from simple colocalization or correlated behaviour.